Angelalign Technology (6699) H2 2025 earnings summary

Executive summary

• Achieved strong global growth in FY2025, with total clear aligner case volume up 48.1% year-over-year to 532,400 cases, driven by both international and Chinese mainland markets.

• Revenue rose 37.8% to USD370.3 million, with global markets (ex-China) revenue up 102.5% and Chinese mainland revenue up 10.1%.

• Net profit increased 163.0% to USD26.3 million, and adjusted net profit rose 63.0% to USD43.8 million.

• Board recommended a final dividend of HKD0.48 per share and a special dividend of HKD4.99 per share.

Financial highlights

• Gross profit increased 38.5% to USD232.9 million; gross margin stable at 62.9%.

• Net profit margin improved to 7.1% from 3.7% year-over-year.

• Adjusted EBITDA rose to USD64.6 million from USD37.7 million.

• Selling and marketing expenses ratio decreased to 32.8% from 39.1%, and administrative expenses ratio fell to 14.1% from 17.2%.

• R&D expenses increased to USD27.6 million, reflecting ongoing investment in innovation.

Outlook and guidance

• Expects continued long-term structural growth in the clear aligner industry, with focus on product innovation, clinical capabilities, and global expansion.

• Plans to strengthen R&D, expand production capacity, enhance legal/IP compliance, and reinforce global sales and support infrastructure.

• Will monitor macroeconomic, regulatory, and geopolitical risks, including healthcare policy changes and international trade dynamics.